パリビズマブが早産児のその後の再発性喘鳴に及ぼす影響

基本情報

NCT ID

NCT01072552

ステータス

完了

試験のフェーズ

-

試験タイプ

観察

目標被験者数

444

治験依頼者名

Tokyo Women's Medical University

概要

The hypothesis of the present study is that the prophylaxis with palivizumab to prevent the severe RS virus infection during the infancy among preterm infants may reduce the risk of subsequent recurrent wheezing in childhood. The infants born between July 1st and December 31st in 2007 with the gestational age between 33 and 35 weeks were enrolled into the study at the end of RS virus infection season, April 2008. The infants were unintentionally divided into two groups, either palivizumab treated or untreated group at the enrollment, because the timing for palivizumab prophylaxis were already ended. The study infants will be followed up until the age of 3 with recording the incidence of either parent reported or physician diagnosed recurrent wheezing. The difference of the incidence of the recurrent wheezing between the groups will be analyzed with Kaplan-Meier method.

対象疾患

依頼者（Sponsor）

実施施設 (1)